[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Oh KC, Zang DY: Primary non-Hodgkin's lymphoma of the bladder with bone marrow involvement. Korean J Intern Med; 2003 Mar;18(1):40-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the bladder with bone marrow involvement.
  • Involvement of the lower urinary tract by advanced non-Hodgkin's lymphoma (NHL) has been reported in up to 13% of cases, but primary NHL of the urinary bladder is very rare.
  • Cystoscopy revealed an edematous broad-based mass on the left lateral wall of the bladder, and transurethral biopsy showed NHL, diffuse large B-cell type.
  • Abdomino-pelvic CT scan demonstrated left-side hydronephrosis and hydroureter with left proximal ureter infiltration and thickening of the left lateral wall of the bladder with perivesical fat infiltration without lymph node enlargement.
  • The lesions of the bladder and left urinary tract were nearly completely regressed after two cycles of systemic cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy with simultaneous restoration of urinary function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow / pathology. Bone Neoplasms / secondary. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, Non-Hodgkin / pathology. Prednisone / administration & dosage. Urinary Bladder Neoplasms / pathology. Vincristine / administration & dosage
  • [MeSH-minor] Adult. Biopsy, Needle. Cystoscopy. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome. Urodynamics

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12760267.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ PMC4531605
  •  go-up   go-down


2. Chitambar CR, Purpi DP, Woodliff J, Yang M, Wereley JP: Development of gallium compounds for treatment of lymphoma: gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate. J Pharmacol Exp Ther; 2007 Sep;322(3):1228-36
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of gallium compounds for treatment of lymphoma: gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate.
  • Clinical studies have shown gallium nitrate to have significant antitumor activity against non-Hodgkin's lymphoma and bladder cancer, thus indicating that gallium-based drugs have potential for further development as antineoplastic agents.
  • In this study, we compared the cytotoxicity of gallium maltolate, a novel gallium compound, with gallium nitrate in lymphoma cell lines, including p53 variant and unique gallium nitrate-resistant cells.
  • Gallium maltolate is incorporated into lymphoma cells to a greater extent than gallium nitrate via both TfR-independent and -dependent pathways; it has significant activity against gallium nitrate-resistant cells and acts independently of p53.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GALLIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17600139.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109518-02; United States / NCI NIH HHS / CA / R01 CA109518; United States / NCI NIH HHS / CA / R01 CA109518-02
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organometallic Compounds; 0 / Pyrones; 0 / Receptors, Transferrin; 0 / Tumor Suppressor Protein p53; 0 / gallium maltolate; 13494-90-1 / gallium nitrate; CH46OC8YV4 / Gallium
  •  go-up   go-down


3. Brennan P, Coates M, Armstrong B, Colin D, Boffetta P: Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia. Br J Cancer; 2000 Apr;82(7):1344-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia.
  • The incidence of non-Hodgkin's lymphoma (NHL) has been increasing rapidly over the last three decades.
  • A total of 12,452 patients contributed 54,308 person-years of follow-up during which time there were 705 second primary neoplasms compared to 592.99 expected (standardized incidence ratio (SIR = 1.19, 95% confidence interval (CI) 1.10-1.28).
  • There were excesses of melanomas of skin (SIR = 2.38, 95% CI 1.92-2.91), lip cancer (SIR = 2.74, 95% CI 1.59-4.38), tongue cancer (SIR = 2.53, 95% CI 1.09-4.99) and bladder cancer (SIR = 1.64, 95% CI 1.19-2.21).
  • There was also over a threefold excess in soft tissue sarcomas (SIR = 3.61, 95% CI 1.80-6.45) and in thyroid cancer (SIR = 3.42, 95% CI 1.56-6.49).
  • The increase in soft tissue sarcomas might be due to shared effects of exposure to chemicals such as phenoxy acid herbicides.
  • The increases in bladder and thyroid cancers are likely to be explained by effects of treatment for NHL.
  • We did not find a chemotherapy related increased risk of myeloid leukaemia among NHL patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Female. Humans. Incidence. Male. Melanoma / epidemiology. Melanoma / etiology. Middle Aged. New South Wales / epidemiology. Registries. Retrospective Studies. Risk Assessment. Skin Neoplasms / epidemiology. Skin Neoplasms / etiology. Sunlight / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Apr 1;67(7):2002-9 [2004317.001]
  • [Cites] Arch Dermatol. 1994 Aug;130(8):1018-21 [8053698.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 5;86(19):1450-7 [8089863.001]
  • [Cites] Int J Epidemiol. 1997 Oct;26(5):945-52 [9363514.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]
  • [Cites] Br J Cancer. 1996 Apr;73(7):945-50 [8611412.001]
  • [Cites] Am J Epidemiol. 1997 Jun 15;145(12):1061-75 [9199536.001]
  • [Cites] Leuk Lymphoma. 1994 Aug;14(5-6):387-94 [7812197.001]
  • (PMID = 10755412.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] SCOTLAND
  • [Other-IDs] NLM/ PMC2374485
  •  go-up   go-down


Advertisement
4. Koike H, Morita T, Tamura Y: [Primary malignant lymphoma of the urinary bladder: a case report]. Nihon Hinyokika Gakkai Zasshi; 2004 May;95(4):675-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary malignant lymphoma of the urinary bladder: a case report].
  • We report a case of primary malignant lymphoma of the urinary bladder.
  • Macrohematuria appeared, and the submucosal tumor was observed by cystoscopy, and A Transurethral bladder biopsy led to a histopathological diagnosis of non-Hodgkin's malignant lymphoma (diffuse lymphoma, large-sized cell type, B-cell type).
  • Clinical stage was IE, but as soon, she was get bilateral hydronephrosis and bladder-ileum fistula.
  • The administration of 6-course CHOP chemotherapy had an excellent effect of disappearing the tumor, bilateral hydronephrosis, and bladder-ileum fistula.
  • [MeSH-major] Lymphoma, B-Cell. Lymphoma, Large B-Cell, Diffuse. Urinary Bladder Neoplasms
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Prednisone / administration & dosage. Remission Induction. Stents. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15198002.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


5. Hughes M, Morrison A, Jackson R: Primary bladder lymphoma: management and outcome of 12 patients with a review of the literature. Leuk Lymphoma; 2005 Jun;46(6):873-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bladder lymphoma: management and outcome of 12 patients with a review of the literature.
  • Primary bladder non-Hodgkin's lymphoma (NHL) is rare.
  • Using the Scotland and Newcastle lymphoma group database, 12 patients with primary bladder lymphoma were identified between 1980 and 2001, the largest single group of patients available to date.
  • Six cases were low-grade extranodal marginal zone lymphoma, 4 diffuse large B-cell lymphoma, one an ALK 1 positive anaplastic large cell lymphoma (ALKoma) and one a low-grade lymphoma unspecified.
  • One patient with high-grade NHL gained complete remission without conventional therapy.
  • Nine patients were treated with single or combined modality surgery, chemotherapy and/or radiotherapy.
  • A review of 88 additional cases in the literature support the findings that primary bladder lymphoma is associated with a good prognosis.
  • Patients with low-grade extranodal marginal zone lymphoma may respond well to simple therapies.
  • Patients with diffuse large B-cell lymphoma respond well to first-line chemotherapy regimens.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Medical Oncology / methods. Prognosis. Registries. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019532.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Fujimura M, Chin K, Sekita N, Kajimoto S, Kamijima S, Suzuki H, Ichikawa T, Mikami K: [Regression of mucosa-associated lymphoid tissue lymphoma of the bladder after antibiotic therapy: a case report]. Hinyokika Kiyo; 2008 Dec;54(12):783-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regression of mucosa-associated lymphoid tissue lymphoma of the bladder after antibiotic therapy: a case report].
  • Transurethral coagulation and a biopsy of the urinary bladder were performed.
  • Histopathological examination of the biopsy revealed non-Hodgkin's lymphoma of the mucosa-associated lymphoid tissue (MALT) type.
  • Results of a computed tomography scan and gallium scintigraphy suggested that it was a primary malignant lymphoma of the urinary bladder.
  • Because of the detection of a Helicobacter pylori (HP) infection in the gastric mucosal biopsy specimens, the patient was subsequently administered HP eradication therapy.
  • Consequently, the lymphoma disappeared and the woman has had no tumor recurrence for the past 25 months.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Amoxicillin / therapeutic use. Cefoperazone / therapeutic use. Cephalosporins / therapeutic use. Clarithromycin / therapeutic use. Female. Helicobacter Infections / drug therapy. Humans. Sulbactam / therapeutic use

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • Hazardous Substances Data Bank. Clarithromycin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19175002.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Cephalosporins; 5J77167P9E / cefcapene pivoxil hydrochloride; 7U75I1278D / Cefoperazone; 804826J2HU / Amoxicillin; H1250JIK0A / Clarithromycin; S4TF6I2330 / Sulbactam
  •  go-up   go-down


7. Liu GH, Li HZ, Wang HJ, Mao QZ, Xia M, Xie Y, Xue C, Wang H, Ji ZG: [Occurrence, types, and therapies of malignant tumors in recipients of renal transplantation]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Jun;31(3):288-91
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Occurrence, types, and therapies of malignant tumors in recipients of renal transplantation].
  • OBJECTIVE: To investigate the types and therapies of malignancies in renal allograft recipients.
  • METHODS: We retrospectively analyzed the occurrence, types, and therapies of malignancies in 498 renal allograft recipients who had received operations in Peking Union Medical College Hospital from May 1986 to October 2008.
  • RESULTS: Among 498 renal allograft recipients, 18 patients (3.6% ) were diagnosed with malignancies, which included bladder cancer (n = 5), renal pyloric cancer or ureteric cancer (n = 4), leukemia or lymphoma (n = 3), hepatic cancer (n = 2), skin cancer, rectum carcinoma, pulmonary carcinoma and thymoma (n = 1 each).
  • Three patients with bladder cancer and one patient with ureteric cancer experienced recurrences 7 to 15 months after operations; among them one bladder cancer patient died.
  • One non-Hodgkin's lymphoma patient died 11 months after chemotherapy.
  • Five cases with advanced unresectable malignancies died 8 to 17 months after the diagnosis.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621511.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Evans DA, Moore AT: The first case of vesico-vaginal fistula in a patient with primary lymphoma of the bladder - a case report. J Med Case Rep; 2007;1:105

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The first case of vesico-vaginal fistula in a patient with primary lymphoma of the bladder - a case report.
  • BACKGROUND: Primary lymphoma of the bladder is a rare condition with less than 100 cases reported in the literature.
  • Cystoscopy revealed a solid tumour throughout the whole bladder wall and a vesico-vaginal fistula.
  • Trans urethral biopsies taken at cystoscopy revealed Non-Hodgkin's Lymphoma.
  • The patient had a nephrostomy inserted and is currently receiving a course of chemotherapy.
  • CONCLUSION: We believe this is the first documented case of primary bladder lymphoma causing a fistula and therefore we suggest that lymphoma should be included in the differential for any patient with a fistula involving the bladder.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Urol Nephrol. 1997;29(3):319-22 [9285304.001]
  • [Cites] J Urol. 1963 Jul;90:58-61 [14047853.001]
  • [Cites] Br J Urol. 1953 Jun;25(2):119-26 [13059372.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):332-6 [11231478.001]
  • [Cites] J Urol. 1990 Dec;144(6):1367-9 [2231929.001]
  • [Cites] Eur Urol. 1992;21(1):85-8 [1606990.001]
  • [Cites] Am J Surg Pathol. 1998 Mar;22(3):373-7 [9500781.001]
  • [Cites] Eur J Surg Oncol. 1987 Aug;13(4):361-4 [3114007.001]
  • [Cites] Urology. 1986 Sep;28(3):235-7 [3750605.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] J Urol. 1970 Mar;103(3):310-3 [5412748.001]
  • [Cites] Pathol Res Pract. 1996 Feb;192(2):160-3; discussion 164-5 [8692717.001]
  • (PMID = 17900354.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2092432
  •  go-up   go-down


9. Ogino J, Kawakatsu C, Hirasawa A, Sato T, Kawamura S, Nishikawa T, Wakabayashi Y: [Primary renal non-Hodgkin's lymphoma presenting as massive macrohematuria and bladder tamponade]. Rinsho Ketsueki; 2001 Nov;42(11):1101-4
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary renal non-Hodgkin's lymphoma presenting as massive macrohematuria and bladder tamponade].
  • A 43-year-old man with macrohematuria and anuresis was admitted, and diagnosed as having bladder tamponade due to coagulates.
  • Abdominal ultrasonography and computed tomography revealed bilateral renal tumors.
  • Percutaneous needle biopsy of the left renal tumor was performed, and the final diagnosis was non-Hodgkin's lymphoma (diffuse mixed, B cell type, CSIIA).
  • After six courses of chemotherapy, the tumor lesions were markedly reduced, and at present there is no evidence of recurrence.
  • [MeSH-major] Hematuria / etiology. Kidney Neoplasms / complications. Lymphoma, Non-Hodgkin / complications. Urinary Bladder Diseases / etiology

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11808078.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Mitropoulos FA, Angelopoulou MK, Siakantaris MP, Rassidakis G, Vayiopoulos GA, Papalampros E, Kalovidouris A, Pangalis GA: Primary non-Hodgkin's lymphoma of the gall bladder. Leuk Lymphoma; 2000 Dec;40(1-2):123-31
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the gall bladder.
  • Primary non-Hodgkin lymphoma of the gallbladder is a very rare location of extranodal non-Hodgkin lymphomas.
  • A patient with a primary non-Hodgkin lymphoma of the gallbladder is reported and in addition, the English literature is reviewed.
  • Clinical presentation, diagnostic evaluation, histopathologic findings, treatment modalities and prognosis of primary gallbladder lymphomas reported up to date are reviewed and discussed.
  • Our patient was diagnosed as a T-cell lymphoblastic lymphoma, after cholecystectomy, and had no evidence of disease elsewhere.
  • She was treated with combination chemotherapy and complete remission was achieved.
  • Review of the literature over a 30-year period revealed only 12 cases of well-documented primary non-Hodgkin lymphoma involvement of the gallbladder, including the present case.
  • Diagnostic investigation included ultrasound of the upper abdomen, computed tomography of the abdomen and pelvis, oral cholecystography, percutaneous cholangiography and endoscopic retrograde cholangiopangreatography.
  • Preoperative diagnosis was established in none of the patients.
  • Treatment modalities included surgery and postoperative chemotherapy and irradiation.
  • Here we document the first reported case of a patient with primary T-cell lymphoblastic non-Hodgkin lymphoma of the gallbladder.
  • Review of the literature shows the existence of non-Hodgkin lymphoma of the gallbladder, its rarity and its general dismal prognosis.
  • [MeSH-major] Gallbladder Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Gallbladder / pathology. Gallbladder / ultrasonography. Gallbladder / ultrastructure. Humans. Methotrexate / administration & dosage. Prednisone / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426613.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; MEVAP protocol
  • [Number-of-references] 33
  •  go-up   go-down


11. Peyromaure M, Van Glabeke E, Leblond V, Barrou B, Delcourt A, Richard F: [Primary lymphoma of the bladder]. Prog Urol; 2000 Dec;10(6):1208-11
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary lymphoma of the bladder].
  • The authors report two cases of primary non-Hodgkin's malignant lymphoma of the bladder.
  • In contra with secondary site, which are not rare, primary malignant lymphomas of the bladder wall are exceptional.
  • These tumours cannot be distinguished from other bladder tumours on the basis of their radiological or endoscopic appearance.
  • Only histology provides the diagnosis.
  • Treatment is mainly based on chemotherapy.
  • [MeSH-major] Lymphoma / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11217561.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Glimelius B, Bergh J, Brandt L, Brorsson B, Gunnars B, Hafström L, Haglund U, Högberg T, Janunger KG, Jönsson PE, Karlsson G, Kimby E, Lamnevik G, Nilsson S, Permert J, Ragnhammar P, Sörenson S, Nygren P: The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions. Acta Oncol; 2001;40(2-3):135-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions.
  • This report by The Swedish Council on Technology Assessment in Health Care (SBU) reviews, classifies, and grades the scientific literature on cancer chemotherapy in some major tumour types, describes the practice of chemotherapy in Sweden, compares practice with scientific knowledge, and analyses the costs and cost-effectiveness of chemotherapy.
  • The report is intended primarily for decision-makers at various levels, both practitioners and administrators.
  • For the final evaluation to be as close to the objective truth as possible, a concerted effort was made to guarantee objectivity and thorough assessment of current knowledge about the effects of chemotherapy on the selected cancers.
  • The tumour types selected for this assessment include firstly those types where three investigations had shown an increased use of chemotherapy in Sweden during the latest decade.
  • These were non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, colorectal cancer and urinary bladder cancer.
  • Secondly, the two tumour types comprising the greatest number of patients treated with chemotherapy in Sweden, breast cancer and haematological malignancies, were included.
  • Among the haematological malignancies, the most prevalent ones, acute myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL), Hodgkin's disease (HD), aggressive non-Hodgkin's lymphoma (NHL) of the large B-cell type and indolent NHL of follicular type were evaluated.
  • Thirdly, ovarian cancer was included since chemotherapy has been extensively used and since, at the time of the planning of this overview, a group of very expensive drugs, the taxanes, had preliminarily shown promising results.
  • A wealth of scientific literature has been published on cancer therapy.
  • The review presented in this report is limited to scientific studies judged to be important for evaluating chemotherapy efficacy.
  • The survey of practice of chemotherapy use involved all departments of surgery, urology, gynaecology, internal medicine including haematologic units, pulmonary medicine and general and gynaecologic oncology at 16 hospitals in two health care regions in Sweden, covering 39% of the Swedish population.
  • During the 4 weeks of the survey, all patients with the diagnoses concerned who received chemotherapy were registered.
  • The working group's general conclusions are summarised in the following points: The literature on the effects of chemotherapy is extensive.
  • Chemotherapy has a well-documented role in the curative and palliative treatment of patients with several types of cancer.
  • The use of chemotherapy is of utmost importance for the possibility of cure in certain tumour types.
  • In other tumours, chemotherapy increases the possibility of cure when added to local and regional treatments, particularly surgery.
  • In the instances of no possibility of cure, chemotherapy may to a variable extent improve both patient survival and well-being.
  • In Sweden chemotherapy is largely used in accordance with that documented in the scientific literature.
  • The extent of both over- and under-treatment seems to be limited but cannot be excluded at the individual patient level.
  • The literature-based knowledge is scientifically of lower quality in the most chemotherapy sensitive tumours than in tumours showing more limited sensitivity.
  • In those days, clinical treatment studies did not fulfil the current high quality requirements.
  • Small life-prolonging effects of chemotherapy are sometimes very well documented in large, high quality scientific studies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasms / drug therapy. Technology Assessment, Biomedical
  • [MeSH-minor] Cost-Benefit Analysis. Decision Making. Drug Costs. Evidence-Based Medicine. Humans. Sweden

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11441927.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 17
  •  go-up   go-down


13. Ansari MS, Nabi G, Singh I, Hemal AK, Pandey G: Colovesical fistula an unusual complication of cytotoxic therapy in a case of non-Hodgkin's lymphoma. Int Urol Nephrol; 2001;33(2):373-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colovesical fistula an unusual complication of cytotoxic therapy in a case of non-Hodgkin's lymphoma.
  • A 65-year old man, a known case of non-Hodgkin's lymphoma of base of the tongue and epiglottis presented with complaints of pneumaturia and faecaluria.
  • He had received the first cycle of cytotoxic therapy (CHOP-regimen).
  • At the end of the cycle he developed febrile neutropenia (circulating granulocyte count <1500/mm3).
  • Cystogram showed air in the bladder area and a fistulous communication to a cavity behind the bladder.
  • CT-scan showed air in the bladder, a fistulous communication between the sigmoid colon and bladder along with an intervening small abscess cavity.
  • On exploration a fistulous communication between the sigmoid and bladder along with an intervening small abscess cavity was found.
  • The bladder was closed in two layers with an omental interposition between it and the sigmoid along with a suprapubic cystostomy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cyclophosphamide / adverse effects. Doxorubicin / adverse effects. Intestinal Fistula / chemically induced. Lymphoma, Non-Hodgkin / drug therapy. Prednisone / adverse effects. Sigmoid Diseases / chemically induced. Tongue Neoplasms / drug therapy. Urinary Bladder Fistula / chemically induced. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1987 May;74(5):362-3 [3594123.001]
  • [Cites] Cancer. 1978 Oct;42(4):1747-59 [709532.001]
  • (PMID = 12092659.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


14. McDonald AC, Nicoll JA, Rampling RP: Non-Hodgkin's lymphoma presenting with spinal cord compression; a clinicopathological review of 25 cases. Eur J Cancer; 2000 Jan;36(2):207-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma presenting with spinal cord compression; a clinicopathological review of 25 cases.
  • The aim of this study was to retrospectively examine 25 patients with newly diagnosed non-Hodgkin's lymphoma (NHL) presenting with spinal cord or cauda equina compression as the first symptom that were referred to our department between 1985 and 1996.
  • At presentation 17 patients were non-ambulatory; dual sphincter impairment was found in 9 patients with a further 8 patients having bladder dysfunction only.
  • All patients had a tissue diagnosis.
  • In this latter group 4 patients were treated palliatively and the remaining 16 patients received combination chemotherapy and/or radical radiation therapy.
  • We urge this diagnosis be considered in all patients presenting with spinal cord compression attributed to malignancy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / complications. Spinal Cord Compression / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10741279.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


15. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL): Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol; 2007 Jan;18(1):149-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
  • BACKGROUND: Central nervous system (CNS) relapse is a devastating and usually fatal complication of aggressive lymphoma.
  • We analyzed the patients treated on protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) between 1990 and 2000, evaluated the rate and prognostic factors for CNS recurrence and developed a risk model trying to identify subsets of patients suitable for future prophylactic strategies.
  • PATIENTS AND METHODS: From 1993 to 2000, 1399 patients [<or=60 years with normal lactate dehydrogenase (LDH) and >60 years irrespective of LDH] were randomized to receive six cycles of combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)-21, CHOP-14 or six cycles of CHOP+etoposide (CHOEP)-21, CHOEP-14 in a 2x2 factorial study design in the NHL-B1/B2 studies.
  • The protocol asked for an intrathecal (i.th.) prophylaxis in patients with lymphoblastic lymphoma only (n=17), but overall 71 patients (71 of 1693=4.2%) received prophylaxis by decision of the treating physicians.
  • Treatment with etoposide also evolved as a prognostic factor because the risk of CNS failure was significantly reduced after CHOEP (P=0.017).
  • Elderly patients presenting with both an elevated LDH and lymphoma involvement in liver, bladder or adrenals had an up to 15-fold risk of spread of the disease to the CNS.
  • Thus, a general prophylaxis for all patients is not warranted, the less so since the effectiveness of i.th. prophylaxis itself is judged controversially.
  • A cumulative 20% incidence of CNS disease in certain prognostic subgroups of elderly patients may render these candidates for i.th. prophylaxis; however, this approach would imply a potential overtreatment of approximately 80% of these patients deemed at high risk.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018708.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VB0R961HZT / Prednisone
  •  go-up   go-down


16. Wazait HD, Chahal R, Sundurum SK, Rajkumar GN, Wright D, Aslam MM: MALT-type primary lymphoma of the urinary bladder: clinicopathological study of 2 cases and review of the literature. Urol Int; 2001;66(4):220-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MALT-type primary lymphoma of the urinary bladder: clinicopathological study of 2 cases and review of the literature.
  • Primary lymphoma of the bladder is a rare non-epithelial bladder tumour.
  • It is usually non-Hodgkin's lymphoma with mucosa-associated lymphoid tissue (MALT) lymphoma being its predominant subtype.
  • We present 2 cases of the MALT-type primary lymphoma of the urinary bladder which were treated in our unit.
  • They were treated successfully with chemotherapy alone.
  • We also present a review of the literature emphasising the clinical presentation, the morphological and immunophenotypic features and the various treatment modalities of this rarely seen bladder pathology.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11385310.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 19
  •  go-up   go-down


17. Rabii R, Mezzour MH, Guessous H, Essaki H, Joual A, Rachid M, Quessar A, Benchekroun S, El Mrini M: [Urogenital lymphoma presenting with obstructive anuria]. Prog Urol; 2004 Feb;14(1):73-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urogenital lymphoma presenting with obstructive anuria].
  • The authors report a case of urogenital lymphoma with multiple sites in a patient presenting with oligo-anuria.
  • After a haemodialysis session and ultrasound-guided right percutaneous nephrostomy, pelvic magnetic resonance imaging (MRI) showed a very large pelvic mass between the bladder and the rectum and transrectal biopsy of the mass confirmed the diagnosis of high-grade malignant non-Hodgkin's lymphoma (NHL) with a type B lymphoblastic phenotype.
  • Treatment consisted of chemotherapy according to the LMB 93 protocol.
  • In the light of this case and a review of the literature, the authors discuss the diagnostic, therapeutic and prognostic aspects of this rare site of lymphoma.
  • [MeSH-major] Anuria / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Urogenital Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15098759.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 15
  •  go-up   go-down


18. Várady E, Deák B, Molnár ZS, Rosta A, Schneider T, Esik O, Eckhardt S: Second malignancies after treatment for Hodgkin's disease. Leuk Lymphoma; 2001 Nov-Dec;42(6):1275-81
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancies after treatment for Hodgkin's disease.
  • The occurrence of treatment-related second malignancy following Hodgkin's disease (HD) has now been recognized as a major problem.
  • The purpose of this study was to review our experience with second malignancies in patients treated for Hodgkin's disease, comparing the results with the international literature data.
  • Second neoplasm developed in 32 cases (4.8%).
  • Seven secondary hematological malignancies were observed: four acute nonlymphocytic leukemias, two non-Hodgkin's lymphomas and one chronic myeloid leukemia.
  • Among patients with second hematological malignancies, the mean age at diagnosis of HD was 44 years and the mean interval until the development of second malignancy was 6.1 years.
  • Five patients received chemo- and radiotherapy and in two cases chemotherapy was used.
  • Twenty-five patients have had solid tumors, affecting lung (5), breast (3), colon (3), stomach (2), urinary bladder (2), head-and-neck (1), thyroid gland (1), esophagus (1), liver (1), pancreas (1), furthermore, three sarcomas and two malignant melanomas were observed.
  • Their mean age at the diagnosis of HD was 46 years and the mean period of latency was 8.3 years.
  • Chemotherapy was applied to nine patients, 16 patients received both chemo- and radiotherapy.
  • Since alkylating agents increase the risk of leukemia and irradiation contributes mainly to other malignancies, future treatment protocols should attempt to reduce the most serious consequence of therapy without compromising the survival.
  • [MeSH-major] Hodgkin Disease / therapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Female. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911408.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. van den Bosch J, Kropman RF, Blok P, Wijermans PW: Disappearance of a mucosa-associated lymphoid tissue (MALT) lymphoma of the urinary bladder after treatment for Helicobacter pylori. Eur J Haematol; 2002 Mar;68(3):187-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disappearance of a mucosa-associated lymphoid tissue (MALT) lymphoma of the urinary bladder after treatment for Helicobacter pylori.
  • A non-Hodgkin's lymphoma of the MALT type of the urinary bladder, stage I A-E, was diagnosed.
  • Radiotherapy was advised, but the patient refused this kind of treatment.
  • Because of the known relationship of a gastric MALT lymphoma and Helicobacter pylori, the patient was treated with HP eradication therapy.
  • Afterwards the lymphoma disappeared.
  • This is the first known case of the disappearance of a MALT lymphoma of the urinary bladder after treatment with HP eradication therapy.
  • [MeSH-major] Helicobacter Infections / drug therapy. Helicobacter pylori. Lymphoma, B-Cell, Marginal Zone / microbiology. Urinary Bladder Neoplasms / microbiology
  • [MeSH-minor] Biopsy. Humans. Immunophenotyping. Kidney Calculi / diagnosis. Kidney Calculi / therapy. Male. Middle Aged. Remission Induction. Urinary Bladder / immunology. Urinary Bladder / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12028368.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


20. Dell'Atti C, Missere M, Restaino G, Carlino S, Cucci E, Ciuffreda M, Sallustio G: Primary lymphoma of the female urethra. Rays; 2005 Jul-Sep;30(3):269-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the female urethra.
  • The case of a 69-year-old female patient come to our observation with the diagnosis of non-Hodgkin's lymphoma on histology and cystoscopy is discussed.
  • CT and NMR for staging and control CT during chemotherapy were performed.
  • They documented marked reduction of the neoformation protruding into the bladder and concentric urethral thickening associated with volumetric stability of intercavoaortic lymph node involvement and stable condition of the other localizations.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Urethral Neoplasms / diagnosis
  • [MeSH-minor] Aged. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512075.001).
  • [ISSN] 0390-7740
  • [Journal-full-title] Rays
  • [ISO-abbreviation] Rays
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


21. Barthelmes L, Thomas KJ, Seale JR: Prostatic involvement of a testicular lymphoma in a patient with myasthenia gravis on long-term azathioprine. Leuk Lymphoma; 2002 Dec;43(12):2425-6
Hazardous Substances Data Bank. AZATHIOPRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic involvement of a testicular lymphoma in a patient with myasthenia gravis on long-term azathioprine.
  • We present a patient who developed non-Hodgkin's lymphoma after eight years of azathioprine treatment for myasthenia gravis.
  • He presented unusually with testicular lymphoma spreading to the prostate and the illness followed a particularly aggressive course.
  • [MeSH-major] Azathioprine / adverse effects. Lymphoma, Large B-Cell, Diffuse / etiology. Myasthenia Gravis / complications. Testicular Neoplasms / etiology
  • [MeSH-minor] Fatal Outcome. Humans. Lymphoma, B-Cell / chemically induced. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / etiology. Male. Middle Aged. Prostatic Neoplasms. Time Factors. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Myasthenia gravis.
  • MedlinePlus Health Information. consumer health - Myasthenia Gravis.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613537.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] MRK240IY2L / Azathioprine
  •  go-up   go-down


22. DeLair SM, White RW, Kurzrock EA: Secondary transitional cell carcinoma and nitrogen mustard treatment. Urology; 2005 Jun;65(6):1226-7
Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary transitional cell carcinoma and nitrogen mustard treatment.
  • Transitional cell carcinoma (TCC) of the bladder in children is a rare occurrence.
  • The role of radiotherapy in the development of secondary malignancies of the bladder remains controversial.
  • We report a case of childhood TCC in a patient in remission from Hodgkin's lymphoma previously treated with non-cyclophosphamide chemotherapy and low-dose nodal radiotherapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Carcinoma, Transitional Cell / chemically induced. Mechlorethamine / adverse effects. Neoplasms, Second Primary / chemically induced. Urinary Bladder Neoplasms / chemically induced
  • [MeSH-minor] Adolescent. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Humans. Lymphatic Irradiation. Male


23. Frankel SR: Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis. Semin Oncol; 2003 Apr;30(2):300-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
  • The components of the apoptotic pathway are targets for anticancer therapy.
  • Bcl-2 protein inhibits apoptosis and confers resistance to treatment with traditional cytotoxic chemotherapy, radiotherapy, and monoclonal antibodies.
  • Randomized clinical trials are currently underway to evaluate the efficacy and tolerability of oblimersen in combination with cytotoxic chemotherapy in chronic lymphocytic leukemia (CLL), multiple myeloma (MM), malignant melanoma, and non-small cell lung cancer.
  • In addition, nonrandomized trials are underway to evaluate oblimersen in non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (AML), and hormone-refractory prostate cancer.
  • Preclinical data support the clinical evaluation of oblimersen in additional tumor types, including chronic myelogenous leukemia, and breast, small cell lung, gastric, colon, bladder (CML), and Merkel cell cancers.
  • Enhancement of the efficacy of anticancer treatments with oblimersen Bcl-2 antisense therapy represents a promising new apoptosis-modulating strategy, and ongoing clinical trials will test this therapeutic approach.
  • [MeSH-major] Apoptosis. Down-Regulation / drug effects. Genes, bcl-2 / genetics. Oligonucleotides, Antisense / therapeutic use. Thionucleotides / therapeutic use. Waldenstrom Macroglobulinemia / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Inc. All rights reserved.
  • (PMID = 12720157.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / Thionucleotides; 85J5ZP6YSL / oblimersen
  • [Number-of-references] 45
  •  go-up   go-down


24. Klasa RJ, Gillum AM, Klem RE, Frankel SR: Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev; 2002 Jun;12(3):193-213
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
  • The components of the apoptotic program are targets for anticancer therapy.
  • Bcl-2 protein inhibits apoptosis and confers resistance to treatment with traditional cytotoxic chemotherapy, radiotherapy, and monoclonal antibodies (mAb).
  • Randomized clinical trials are currently underway to evaluate the efficacy and tolerability of oblimersen in combination with cytotoxic chemotherapy in chronic lymphocytic leukemia, multiple myeloma, malignant melanoma, and non-small cell lung cancer.
  • In addition, nonrandomized trials are under way to evaluate oblimersen in non-Hodgkin's lymphoma, acute myeloid leukemia, and hormone-refractory prostate cancer.
  • Preclinical data also support the clinical evaluation of oblimersen in additional tumor types, including chronic myelogenous leukemia and breast, small cell lung, gastric, colon, bladder, and Merkel cell cancers.
  • Enhancement of the efficacy of anticancer treatments with oblimersen Bcl-2 antisense therapy represents a promising new apoptosis-modulating strategy, and ongoing clinical trials will test this therapeutic approach.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Oligonucleotides, Antisense / pharmacology. Proto-Oncogene Proteins c-bcl-2 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12162702.001).
  • [ISSN] 1087-2906
  • [Journal-full-title] Antisense & nucleic acid drug development
  • [ISO-abbreviation] Antisense Nucleic Acid Drug Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Oligonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger
  • [Number-of-references] 124
  •  go-up   go-down


25. Krishna RP, Lal R, Sikora SS, Yachha SK, Pal L: Unusual causes of extrahepatic biliary obstruction in children: a case series with review of literature. Pediatr Surg Int; 2008 Feb;24(2):183-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper highlights the etiology, diagnosis, management and outcome in nine unusual cases of extrahepatic biliary obstruction in children.
  • However, nine children (aged 1.5-15 years) presented with uncommon causes like (1) idiopathic benign non-traumatic inflammatory stricture (n = 3), (2) idiopathic fibrosing chronic pancreatitis (n = 2), (3) post-cholecystectomy type 4 benign biliary stricture (n = 1), (4) post-acute pancreatitis pseudo-cyst of pancreas (n = 1), (5) non-Hodgkin's lymphoma (NHL) with extramural common bile duct compression and gall bladder perforation (n = 1), and (6) Langerhan cell histiocytosis (LCH, n = 1).
  • The patients with NHL and LCH were referred for chemotherapy after establishing tissue diagnosis at laparotomy.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1995 Jun;130(6):597-602; discussion 602-4 [7763167.001]
  • [Cites] Ann Surg. 1985 Dec;202(6):720-4 [4073984.001]
  • [Cites] Cancer. 1995 Apr 1;75(7):1669-77 [8826926.001]
  • [Cites] Ann Surg. 1980 Jul;192(1):33-7 [7406561.001]
  • [Cites] J Pediatr Surg. 1995 Jun;30(6):777-80 [7666305.001]
  • [Cites] Am J Surg. 1983 Mar;145(3):343-8 [6837858.001]
  • [Cites] Lancet. 2003 Apr 12;361(9365):1293-5 [12699969.001]
  • [Cites] JOP. 2006 May 09;7(3):262-73 [16685107.001]
  • [Cites] Ann Surg. 1989 May;209(5):532-8; discussion 538-40 [2705818.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):659-61 [4027545.001]
  • [Cites] Surgery. 1992 Nov;112(5):866-71 [1332203.001]
  • [Cites] J Pediatr Surg. 2006 Dec;41(12):1987-91 [17161188.001]
  • [Cites] Hepatogastroenterology. 1992 Aug;39(4):333-6 [1427579.001]
  • [Cites] J Pediatr Surg. 2005 Aug;40(8):1335-40 [16080944.001]
  • [Cites] Br J Surg. 1989 Aug;76(8):849-52 [2765843.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):430-41 [10973393.001]
  • [Cites] J Pediatr Surg. 2006 Nov;41(11):1889-93 [17101365.001]
  • [Cites] Dig Dis Sci. 2002 Jun;47(6):1230-5 [12064796.001]
  • [Cites] Surgery. 2003 Sep;134(3):496-500 [14555939.001]
  • [Cites] Am J Gastroenterol. 1994 Nov;89(11):2063-5 [7942738.001]
  • [Cites] Br J Surg. 2003 Jul;90(7):845-9 [12854111.001]
  • [Cites] J Am Coll Surg. 1995 Jan;180(1):101-25 [8000648.001]
  • [Cites] J Am Coll Surg. 2005 Dec;201(6):862-9 [16310689.001]
  • [Cites] Surgery. 2001 Jul;130(1):55-9 [11436012.001]
  • [Cites] Clin Radiol. 2003 Apr;58(4):269-78 [12662947.001]
  • [Cites] Gut. 1998 Nov;43(5):715-20 [9824357.001]
  • [Cites] Dig Surg. 2006;23(5-6):304-12 [17164542.001]
  • [Cites] J Pediatr Surg. 2001 Dec;36(12):1792-5 [11733908.001]
  • (PMID = 18071716.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


26. Schaapveld M, Visser O, Louwman MJ, de Vries EG, Willemse PH, Otter R, van der Graaf WT, Coebergh JW, van Leeuwen FE: Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol; 2008 Mar 10;26(8):1239-46
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study.
  • PURPOSE: To assess the risk of secondary nonbreast cancers (SNBCs) in a recently treated population-based cohort of breast cancer patients focused on the association with treatment and prognostic implications.
  • SIRs were elevated for cancers of the esophagus, stomach, colon, rectum, lung, uterus, ovary, kidney, and bladder cancers, and for soft tissue sarcomas (STS), melanoma, non-Hodgkin's lymphoma, and acute myeloid leukemia (AML).
  • Among patients younger than 50 years, radiotherapy was associated with an increased lung cancer risk (hazard ratio [HR] = 2.31; 95% CI, 1.15 to 4.60) and chemotherapy with decreased risk for all SNBCs (HR = 0.78; 95% CI, 0.63 to 0.98) and for colon and lung cancer.
  • Among patients age 50 years and older, radiotherapy was associated with raised STS risk (HR = 3.43; 95% CI, 1.46 to 8.04); chemotherapy with increased risks of melanoma, uterine cancer, and AML; and hormonal therapy with all SNBCs combined (HR = 1.10; 95% CI, 1.01 to 1.21) and uterine cancer (HR = 1.78; 95% CI, 1.40 to 2.27).
  • [MeSH-major] Breast Neoplasms / therapy. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Incidence. Middle Aged. Netherlands / epidemiology. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323547.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


27. Murgo AJ: Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist; 2001;6 Suppl 2:22-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The National Cancer Institute is working cooperatively with research centers across the U.S. to evaluate its clinical activity in hematologic malignancies, such as acute promyelocytic leukemia, acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, chronic lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma.
  • It is also supporting research in solid tumors, such as advanced hormone-refractory prostate cancer and renal cell cancer and in cervical cancer and refractory transitional cell carcinoma of the bladder.
  • The safety and pharmacokinetics of arsenic trioxide are also being evaluated in pediatric patients with refractory leukemia and lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arsenicals / therapeutic use. Clinical Trials as Topic. Hematologic Neoplasms / drug therapy. Oxides / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11331437.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 27
  •  go-up   go-down


28. Yildiz O, Ozguroglu M, Yanmaz MT, Turna H, Kursunoglu SG, Antonov M, Serdaroglu S, Demirkesen C, Buyukunal E: Paraneoplastic pemphigus associated with fludarabine use. Med Oncol; 2007;24(1):115-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 51-yr-old man presented to the oncology clinic with mucocutaneous skin lesions after six cycles of fludarabine for non-Hodgkin's lymphoma.
  • The indirect immunofluorescence on rat bladder showed intercellular binding of IgG.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Lymphoma, Non-Hodgkin / drug therapy. Paraneoplastic Syndromes / chemically induced. Pemphigus / chemically induced. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2001 Jun;144(6):1255-61 [11422053.001]
  • [Cites] N Engl J Med. 1990 Dec 20;323(25):1729-35 [2247105.001]
  • [Cites] Rev Med Interne. 2005 Jul;26(7):557-71 [15996570.001]
  • [Cites] Vestn Dermatol Venerol. 1990;(2):50-2 [2188462.001]
  • [Cites] Br J Haematol. 1994 Nov;88(3):649-52 [7819085.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):730-1 [8664199.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1695-700 [8400226.001]
  • [Cites] Br J Dermatol. 1999 Oct;141(4):739-46 [10583130.001]
  • (PMID = 17673821.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunoglobulin G; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


29. Lee JS, Pei-Lin Ng P, Tao M, Lim WT: Paraneoplastic pemphigus resembling linear IgA bullous dermatosis. Int J Dermatol; 2006 Sep;45(9):1093-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He had stage IIIA follicular small cell cleaved non-Hodgkin's lymphoma diagnosed 5 years previously, and had received several lines of palliative chemotherapy, including two courses of chlorambucil, six cycles of cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP), and two four-cycle courses of rituximab, with disease stabilization at the time of presentation.
  • Indirect immunofluorescence on monkey esophagus was positive for anti-intercellular antibody at a titre of 1/160 and positive on rat bladder at a titre of 1/80.
  • A presumptive diagnosis of paraneoplastic pemphigus was made.
  • He declined rituximab therapy.
  • [MeSH-minor] Aged. China. Diagnosis, Differential. Fatal Outcome. Humans. Male. Skin / immunology. Skin / pathology

  • Genetic Alliance. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16961519.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin A
  •  go-up   go-down


30. Jakupec MA, Keppler BK: Gallium in cancer treatment. Curr Top Med Chem; 2004;4(15):1575-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gallium in cancer treatment.
  • Remarkable clinical activity in lymphomas and bladder cancer has been documented in clinical studies employing intravenous gallium nitrate, which is currently being re-evaluated in non-Hodgkin's lymphoma.
  • An improved therapeutic index is expected to result from prolonged exposure to low steady-state plasma gallium levels.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gallium / therapeutic use. Neoplasms / drug therapy. Organometallic Compounds / therapeutic use
  • [MeSH-minor] DNA Replication / drug effects. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. GALLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15579097.001).
  • [ISSN] 1568-0266
  • [Journal-full-title] Current topics in medicinal chemistry
  • [ISO-abbreviation] Curr Top Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organometallic Compounds; CH46OC8YV4 / Gallium
  • [Number-of-references] 116
  •  go-up   go-down






Advertisement